CL2022002699A1 - Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. - Google Patents
Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton.Info
- Publication number
- CL2022002699A1 CL2022002699A1 CL2022002699A CL2022002699A CL2022002699A1 CL 2022002699 A1 CL2022002699 A1 CL 2022002699A1 CL 2022002699 A CL2022002699 A CL 2022002699A CL 2022002699 A CL2022002699 A CL 2022002699A CL 2022002699 A1 CL2022002699 A1 CL 2022002699A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- multiple sclerosis
- tyrosine kinase
- kinase inhibitor
- relapsing multiple
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente se proporcionan métodos para tratar la esclerosis múltiple recidivante (RMS) en un sujeto que lo necesita, al administrar al sujeto alrededor de 200 mg de fenebrutinib dos veces por día, o una cantidad equivalente de una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US202063051767P | 2020-07-14 | 2020-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002699A1 true CL2022002699A1 (es) | 2023-03-31 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002699A CL2022002699A1 (es) | 2020-04-03 | 2022-09-30 | Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230149395A1 (es) |
| EP (1) | EP4125906A1 (es) |
| JP (1) | JP2023520469A (es) |
| KR (1) | KR20220163986A (es) |
| CN (1) | CN115916205A (es) |
| AU (1) | AU2021249129A1 (es) |
| BR (1) | BR112022019846A2 (es) |
| CA (1) | CA3177390A1 (es) |
| CL (1) | CL2022002699A1 (es) |
| IL (1) | IL296990A (es) |
| MX (1) | MX2022012310A (es) |
| TW (1) | TW202203925A (es) |
| WO (1) | WO2021202825A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230171449A (ko) | 2021-05-14 | 2023-12-20 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 공결정질 형태 |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| AU2017227929B2 (en) | 2016-02-29 | 2022-06-30 | F. Hoffmann-La Roche Ag | Dosage form compositions comprising an inhibitor of Bruton's tyrosine kinase |
-
2021
- 2021-04-01 US US17/995,259 patent/US20230149395A1/en active Pending
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko unknown
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
- 2021-04-01 AU AU2021249129A patent/AU2021249129A1/en active Pending
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en active Application Filing
- 2021-04-01 TW TW110112266A patent/TW202203925A/zh unknown
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021249129A1 (en) | 2022-10-20 |
| BR112022019846A2 (pt) | 2022-11-22 |
| WO2021202825A1 (en) | 2021-10-07 |
| CA3177390A1 (en) | 2021-10-07 |
| JP2023520469A (ja) | 2023-05-17 |
| TW202203925A (zh) | 2022-02-01 |
| MX2022012310A (es) | 2022-10-27 |
| EP4125906A1 (en) | 2023-02-08 |
| US20230149395A1 (en) | 2023-05-18 |
| KR20220163986A (ko) | 2022-12-12 |
| CN115916205A (zh) | 2023-04-04 |
| IL296990A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002699A1 (es) | Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| UY39529A (es) | Nuevos agentes antivirales derivados de espiropirrolidina | |
| AR083957A1 (es) | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica | |
| ATE344029T1 (de) | Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern | |
| ES2144119T3 (es) | Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada. | |
| AR033175A1 (es) | Usos farmaceuticos de bisfosfonatos | |
| ECSP099376A (es) | Inhibidores de la actividad de la akt | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| MX2022008875A (es) | Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr). | |
| UY26724A1 (es) | Métodos y composiciones para tratar el virus de la hepatitis c | |
| PT971713E (pt) | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao | |
| YU81991A (sh) | Sinergističke terapeutske kompozicije i postupci | |
| BR112022026186A2 (pt) | Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras | |
| CO5700723A2 (es) | Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca | |
| CY1105787T1 (el) | Θepαπευτικη αντιμετωπιση η προληψη της ατροφιας του ουροποιογεννητικου συστηματος και τα συμπτωματα της σε γυναικες | |
| AR052830A1 (es) | Regimen de cladribina para tratar esclerosis multiple | |
| ECSP22081150A (es) | Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica | |
| CL2022002317A1 (es) | Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. | |
| CO2022015428A2 (es) | Compuesto de oxofenilarsina deuterada y uso del mismo | |
| AR117626A1 (es) | COMPOSICIÓN QUE COMPRENDE INHIBIDOR DE LA a-1 PROTEINASA ALTAMENTE CONCENTRADO Y PROCEDIMIENTO PARA LA OBTENCIÓN DE LA MISMA | |
| ES2194933T3 (es) | Inhibidores de la agregacion plaquetaria. | |
| CO5590922A2 (es) | Uso de istradefilina (kw-6002) para el tratamiento de trastornos de la conducta | |
| AR126166A1 (es) | Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos |